Form 4: Werewolf Therapeutics Director Sells Shares

A director at Werewolf Therapeutics, Luke Evnin, sold a significant number of common shares across three transactions in early January 2026, pursuant to a pre-established 10b5-1 plan.

Summary

• Luke Evnin, a Director of Werewolf Therapeutics, Inc. (HOWL), reported the sale of common stock.
• The transactions occurred on January 8, 2026, January 9, 2026, and January 12, 2026.
• A total of 7,716 shares were sold on January 8, 2026, at a weighted average price of $0.63 per share.
• An additional 24,678 shares were sold on January 9, 2026, at a weighted average price of $0.61 per share.
• A further 58,980 shares were sold on January 12, 2026, at a weighted average price of $0.57 per share.
• These sales were executed under a Rule 10b5-1 trading plan established on September 24, 2025.
• Following these transactions, the indirect beneficial ownership of shares decreased from 2,393,527 to 2,309,869.
• The shares are held indirectly through various MPM entities, where Luke Evnin holds management positions.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling, even if pre-planned, especially given the declining stock price during the sale period. This suggests a lack of immediate positive catalysts or a belief that the stock may not appreciate significantly in the near term.

Positives

• The sales were conducted under a pre-established Rule 10b5-1 plan, indicating they were scheduled in advance and not necessarily a reaction to recent negative company-specific news.

Negatives

• A director, albeit indirectly, sold a substantial number of shares, totaling 91,374 shares.
• The sales occurred at progressively lower prices, from $0.63 to $0.57, suggesting a declining stock price during the transaction period.
• Insider selling, even under a 10b5-1 plan, can be perceived negatively by the market as it reduces insider alignment with shareholder interests.

Risks

• The declining share price at which the sales occurred could indicate underlying market concerns or a lack of positive catalysts for Werewolf Therapeutics.
• Significant insider selling, even if pre-planned, might signal a lack of confidence in the company's near-term growth prospects by those closest to the operations.

Future Outlook

NA

Industry Context

This filing reflects an insider transaction within the biotechnology sector. While the sales were pre-planned, the declining price trend during the sales period could be indicative of broader market sentiment towards early-stage biotech companies or specific concerns within the oncology therapeutic area, where Werewolf Therapeutics operates.

Related Party Transactions

• The sales were conducted by entities (MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, MPM Oncology Innovations Fund, L.P.) where Luke Evnin, a director, holds management positions and has a pecuniary interest.

Stakeholder Impact

• Shareholders: May perceive the insider selling as a negative signal, potentially leading to downward pressure on the stock price.
• Employees: No direct impact mentioned, but a declining stock price could affect equity compensation value.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

While the insider selling is a negative signal, particularly given the declining price trend, the transactions were executed under a pre-established 10b5-1 plan, which mitigates the immediate negative interpretation as a reaction to new adverse information. However, the consistent selling at lower prices by a director suggests limited near-term upside potential. Investors should hold and monitor for further company-specific news or changes in insider sentiment, as the pre-planned nature prevents a 'sell' recommendation based solely on this filing.

Keywords

Werewolf Therapeutics, HOWL, SEC Form 4, Insider Selling, Luke Evnin, Director, Stock Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals